As several big pharma companies drop Parkinson’s projects, attention turns to gene therapies and repurposing diabetes drugs.
But forecasts of over $3bn in annual peak sales from Viela’s portfolio look steep.
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.
SEL-212 fails to beat Krystexxa in phase II, but why did Sobi pay $100m for the asset in June and then put it into phase III?
The number of novel, pivotal-stage projects in big pharma pipelines has plunged – just as Covid-19 put the brakes on deal making.
Launch phase is a challenging time for drug developers, so consider the likes of Biohaven, Esperion and, most recently, Urogen, as they brave locked-down markets.
January saw Aimmune receive an FDA approval for Palforzia, a first for peanut allergy, alongside decisions for Blueprint Medicines and Horizon Therapeutics.